A phase I trial of a pharmacodynamically-conceived decitabine/thioguanine combination in patients with advanced myeloid malignancies.
Todd Rosenblat(Columbia University Irving Medical Center), Mark G. Frattini(Presbyterian Hospital), Hakim Djaballah(High Throughput Biology (United States)), Jacquelyn Gonzales(Columbia University Irving Medical Center), Joseph G. Jurcic(Memorial Sloan Kettering Cancer Center), Leah J. Hogdal(Harvard University), Joseph M. Scandura(Cornell University), Diana Carrillo(Columbia University Irving Medical Center), Katherine Harwood(Morgan Stanley Children's Hospital), Martin Santos(Columbia University Irving Medical Center), Azra Raza(University of Illinois Chicago), Jennifer L. Crombie(Dana-Farber Cancer Institute), Rong Zhang(Columbia University Irving Medical Center), Ruth Santos(Columbia University Irving Medical Center), J. Gregory Mears(Columbia University Irving Medical Center), Anthony Letai(Dana-Farber Cancer Institute), Glorymar Ibáñez, Mark Heaney(Immunovaccine (Canada))
Cited by 0
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k